Retatrutide is a GGG tri-agonist aimed at GLP-1 and GIP receptors, similar to conventional GLP-1 agonists, but it also distinctly stimulates the glucagon receptor. This additional activation of the glucagon receptor encourages the production of glucagon, facilitating the breakdown of fats in storage and glycogen, thus boosting basal metabolic rates for sustained fat reduction. By influencing GLP-1 and GIP receptors, it also supports slower gastric emptying and manages hunger, providing a multi-faceted strategy for investigating obesity, setting it apart from the earlier GLP-1 agonists.